Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00736151
Other study ID # NW-1029/001/II/2003
Secondary ID EUDRACT Number 2
Status Completed
Phase Phase 2
First received August 13, 2008
Last updated August 6, 2009
Start date May 2004

Study information

Verified date August 2009
Source Newron
Contact n/a
Is FDA regulated No
Health authority Austria: EthikkommissionCzech Republic: Ethics CommitteeIndia: Drugs Controller General of IndiaItaly: The Italian Medicines AgencyPoland: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine the effects of various increasing doses of Ralfinamide in patients with neuropathic pain.


Recruitment information / eligibility

Status Completed
Enrollment 272
Est. completion date
Est. primary completion date April 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Male or female patients

- Females post-menopausal for at least 12 months, 24 months in India, Poland, and Austria

- Diagnosed by neurologist with current neuropathic pain

Exclusion Criteria:

- See inclusion criteria

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Ralfinamide
Oral tablets administered at rising doses of 80 - 320 mg/day

Locations

Country Name City State
Austria Universitatsklinik Fur Neurologie Graz
Austria Universitatsklinik Fur Neurologie Innsbruck
Austria LKH Klagenfurt
Austria General Hospital AKH Wien
Czech Republic Fakultni nemocnice u svate' Anny v Brne Brno
Czech Republic Fakultni nemocnice Brno Brno-Bhunice
Czech Republic University Hospital Olomouc Olomouc
Czech Republic Univercity Hospital Pilsen Pizen
Czech Republic Na Homolce Hospital Prague
Czech Republic Fakultni Thomayerova nemocnices poliklinikou Praha
India Neurology Centre Ahmedabad
India M.S. Ramaiah Medical Bangalore
India R.S. R'S Trinity Acute Care Hospital Chennai
India Sri Ramachandra medical College Chennai
India Care Hospital Hyderabad
India Chowpatty Medical Centre Mumbai
India Brain and Mind Institute Nagpur
India Apollo Hospital Pradesh
India Brain Waves Clinic Pune
India Vijaya Health Centre Vadapalani
Italy Ospedali Riuniti di Bergamo Bergamo
Italy Ce. S.I. Fondazione Universitaria Chieti
Italy Ospedale Clinicizzato Universitario SS. Annunziata Chieti
Italy Arcispedale Sant'Anna Ferrara
Italy Azienda Ospedaliera San Martino Genova
Italy Universita degli Studi di Genova Genova
Italy Ospedale Luigi Sacco Grassi
Italy Ospedale Civile Umberto I Mestre
Italy Ospedale San Raffaele Milano
Italy Istituto Scientifico di Riabilazione di Montescano Montescano
Italy Policlinico Universitario Federico II Napoli
Italy UCADH Pavia
Italy Presidio Ospedaliero Monteluce Perugia
Italy Universita degli Studi di Roma Roma
Italy Policlinico G.B. Rossi Verona
Poland Centrum Medyczne Osteomed Bialobrzeska
Poland Centrum Kliniczno Badawcze Elblag
Poland Wojewodzki Szpiyal Spejalistyczny Gdansk
Poland Center Of Clinical Neurology Krakow
Poland Osrodek Baden Klinicznych Lublin
Poland Wojskowy Instytut Medyczny Warszawa
Poland Wroclaw Medical University Wroclaw
Poland Oddzial Neurologiczny Zgierz
United Kingdom Gartnavel General Hospital Glasgow
United Kingdom Barta and The London NHS Trust London
United Kingdom Kings College Hospital London
United Kingdom Solihull Hospital West Midlands

Sponsors (1)

Lead Sponsor Collaborator
Newron

Countries where clinical trial is conducted

Austria,  Czech Republic,  India,  Italy,  Poland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of pain intensity Baseline to week 8 or last visit No
Secondary The incidence of adverse events From baseline to week 8 or last visit No
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Completed NCT05235191 - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Not yet recruiting NCT05949554 - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn NCT05052645 - Ear Acupuncture for Neuropathic Pain N/A
Completed NCT02930551 - Neuromas as the Cause of Pain N/A
Completed NCT02824588 - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain N/A
Completed NCT02866396 - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Active, not recruiting NCT02560545 - Cannabinoids Effects on the Pain Modulation System N/A
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Not yet recruiting NCT02246517 - The Effect of N2O on Chronic Neuropathic Pain Patients Phase 0
Completed NCT02099890 - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Phase 3
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Completed NCT01718821 - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients N/A
Completed NCT01669967 - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin N/A
Completed NCT01207596 - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Phase 4
Completed NCT01201317 - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Phase 2